Leading Companies Reinforcing Their Presence in the Biosimilar Growth Hormones Market

The biosimilar growth hormones industry is positioned for significant expansion over the coming years, driven by several key developments in the healthcare sector. With advances in biosimilar approvals and changing treatment preferences, this market is set to transform the way growth hormone therapies are delivered and accessed globally. Let's explore the current market size, main players, emerging trends, and segment outlook within this evolving industry.

Market Size Outlook and Growth Potential for Biosimilar Growth Hormones
The biosimilar growth hormones market is anticipated to grow rapidly, reaching a valuation of $1.46 billion by 2030. This expansion corresponds to a compound annual growth rate (CAGR) of 10.5%. Key factors contributing to this increase include the expiration of patents on branded growth hormones, a rise in regulatory approvals for biosimilars, a surge in self-administration treatment options, heightened awareness around growth disorders, and growing healthcare spending in emerging regions. Notable trends influencing market dynamics involve increased uptake of affordable biosimilar therapies, a growing demand for treatments across both pediatric and adult populations, a preference for subcutaneous self-injection routes, the proliferation of online pharmacies and specialty clinics, and more favorable regulatory environments for biosimilar products.

Download a free sample of the biosimilar growth hormones market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3391&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Who Are the Leading Companies Driving the Biosimilar Growth Hormones Market?
Several prominent firms dominate the biosimilar growth hormones landscape, including Amega Biotech, Biosidus S.A., Eli Lilly and Company, Ferring Pharmaceuticals, Genetech Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Sanofi S.A., USV Private Limited, Zhongshan Hygene Biopharm Co. Ltd., Biopartners, LG Chem, Boehringer Ingelheim International GmbH, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Gedeon Richter Plc., Genor Biopharma Co. Ltd., Hetero Drugs Limited, Intas Pharmaceuticals Ltd., Lupin Limited, Mabion S.A., Mundipharma International Limited, Panacea Biotec Limited, Pfenex Inc., and PlantForm Corporation.
In a notable development in October 2023, Amgen, a biotechnology company based in the United States, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition is part of Amgen's strategic plan to bring innovative medicines to patients suffering from serious illnesses. Horizon's key products include Tepezza, which targets thyroid eye disease; Krystexxa, for chronic refractory gout; and Uplizna, used in treating neuromyelitis optica spectrum disorder. The deal is expected to accelerate revenue growth and strengthen cash flow, providing enhanced support for ongoing research and innovation. Horizon Therapeutics is based in Ireland.

Emerging Trends Transforming the Biosimilar Growth Hormones Field
Leading companies in the biosimilar growth hormones market are focusing on developing therapies that improve both treatment effectiveness and cost accessibility for individuals with growth hormone deficiencies. Human growth hormone solutions encompass medical interventions aimed at stimulating or replacing natural HGH to address growth issues or for anti-aging benefits.
For example, in June 2023, Pfizer Inc., a US pharmaceutical giant, alongside OPKO Health Inc., obtained FDA approval for NGENLA (somatrogon-ghla). This product is a once-weekly injectable human growth hormone intended for pediatric patients with growth hormone deficiency (GHD). The long-acting nature of NGENLA presents an alternative to daily injections, enhancing convenience and adherence for patients and caregivers. The approval was granted following clinical trials that confirmed the treatment's safety and efficacy, marking a significant milestone in the evolution of growth hormone therapies.

View the full biosimilar growth hormones market report:
https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Segment Insights and Market Forecast for Biosimilar Growth Hormones
This market is categorized into several key segments:
1) Route of Administration: Subcutaneous, Intramuscular, Oral
2) Application: Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Prader Willi Syndrome, and Other Applications
3) Distribution Channel: Hospital and Retail Pharmacies, Online Pharmacies/ePharmacies, Specialty Clinics.

Within these, subcategories include:
- Subcutaneous administration divided into self-administration and professional administration
- Intramuscular administration split between pediatric and adult care
- Oral forms including tablets and capsules

These classifications help provide a clear picture of how the biosimilar growth hormones market is structured and the various ways treatments are delivered to patients.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.